{"title":"Melanocortins \u0026 sexual health","description":null,"products":[{"product_id":"mt-1","title":"MT-1","description":"\u003ch1 dir=\"ltr\"\u003e\u003cspan\u003eMT-1 (Afamelanotide) 10 mg Research Vial\u003c\/span\u003e\u003c\/h1\u003e\n\u003cdiv dir=\"ltr\" align=\"left\"\u003e\n\u003ctable\u003e\n\u003ccolgroup\u003e\n\u003ccol width=\"180\"\u003e\n\u003ccol width=\"444\"\u003e\n\u003c\/colgroup\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eAlternate name\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/td\u003e\n\u003ctd\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eAfamelanotide; Melanotan I; [Nle4, D-Phe7]-alpha-MSH\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eCompound class\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/td\u003e\n\u003ctd\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eSynthetic 13-amino-acid alpha-MSH analog; melanocortin receptor agonist\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eFormat\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/td\u003e\n\u003ctd\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eVial\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eStrength(s)\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/td\u003e\n\u003ctd\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003e10 mg per vial\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eSequence\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/td\u003e\n\u003ctd\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eAc-Ser-Tyr-Ser-Nle-Glu-His-D-Phe-Arg-Trp-Gly-Lys-Pro-Val-NH2\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eMolecular formula\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/td\u003e\n\u003ctd\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eC78H111N21O19\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eMolecular weight\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/td\u003e\n\u003ctd\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003e1646.8 g\/mol\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eCAS number\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/td\u003e\n\u003ctd\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003e75921-69-6\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003ePurity\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/td\u003e\n\u003ctd\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eStated per lot on the Certificate of Analysis\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eManufacturer\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/td\u003e\n\u003ctd\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003ePEPTYVA, Mexico\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003c\/div\u003e\n\u003ch2 dir=\"ltr\"\u003e\u003cstrong\u003eWhat is MT-1?\u003c\/strong\u003e\u003c\/h2\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eMT-1 afamelanotide is offered here as a 10 mg research vial. MT-1 is the research name for afamelanotide, also known as Melanotan I: a synthetic 13-amino-acid analog of alpha-melanocyte-stimulating hormone (alpha-MSH). PEPTYVA manufactures this vial in Mexico, and Peptides Vallarta sells it for laboratory research use only. It is not Scenesse and it is not a medicine.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eAfamelanotide differs from native alpha-MSH at two positions: norleucine replaces methionine at position 4, and D-phenylalanine replaces L-phenylalanine at position 7. These changes were designed to give a stronger receptor affinity and a longer biological half-life than the natural hormone.\u003c\/span\u003e\u003c\/p\u003e\n\u003ch2 dir=\"ltr\"\u003e\u003cstrong\u003eHow does MT-1 act at melanocortin receptors?\u003c\/strong\u003e\u003c\/h2\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eAfamelanotide is a melanocortin receptor agonist that binds predominantly to the melanocortin 1 receptor (MC1R), according to the FDA label for Scenesse. MC1R is expressed on melanocytes, the pigment-producing cells of the skin.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eBecause of that receptor profile, afamelanotide is studied in photobiology and pigment-cell research, where MC1R signaling in melanocytes is the main read-out.\u003c\/span\u003e\u003c\/p\u003e\n\u003ch2 dir=\"ltr\"\u003e\u003cstrong\u003eWhat is the approved afamelanotide product?\u003c\/strong\u003e\u003c\/h2\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eAfamelanotide is approved as Scenesse, a 16 mg bioresorbable implant. The European Commission authorized it on 22 December 2014, under exceptional circumstances, for \"prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP)\".\u003c\/span\u003e\u003c\/p\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eFDA approved Scenesse on 8 October 2019 \"to increase pain-free light exposure in adult patients with a history of phototoxic reactions from erythropoietic protoporphyria (EPP)\". The current US label, revised in August 2024, keeps the indication limited to adults and lists warnings for hypersensitivity and for skin monitoring.\u003c\/span\u003e\u003c\/p\u003e\n\u003ch2 dir=\"ltr\"\u003e\u003cstrong\u003eWhat did the main clinical trials study?\u003c\/strong\u003e\u003c\/h2\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eTwo randomized, double-blind, placebo-controlled clinical trials published in 2015 tested the 16 mg implant in people with EPP: 74 participants in the European Union and 94 in the United States. The primary end point was the number of hours of direct sunlight exposure without pain.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eThe authors reported longer pain-free exposure in the afamelanotide groups than with placebo and described adverse events as mostly mild. These data describe the Scenesse implant in a rare light-sensitivity disorder only.\u003c\/span\u003e\u003c\/p\u003e\n\u003ch2 dir=\"ltr\"\u003e\u003cstrong\u003eWhy does the implant evidence not apply to this vial?\u003c\/strong\u003e\u003c\/h2\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eThe trial data and both approvals belong to one specific product: the Scenesse 16 mg implant, with its own formulation, release characteristics, manufacturing dossier and labeling. This PEPTYVA vial differs in format and strength and is not covered by the FDA or EMA approvals.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eFor that reason, evidence for Scenesse cannot be transferred to this vial, and the regulatory approval does not extend to this research material. The A grade on this page refers to the approved active ingredient, not to the vial.\u003c\/span\u003e\u003c\/p\u003e\n\u003ch2 dir=\"ltr\"\u003e\u003cstrong\u003eHow does MT-1 differ from MT-2?\u003c\/strong\u003e\u003c\/h2\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eMT-1 and MT-2 are both alpha-MSH analogs, but they differ in structure, receptor profile and regulatory history. MT-1 is a linear 13-residue peptide that binds mainly MC1R and is approved as Scenesse. MT-2, our melanotan II 10 mg research peptide, is a shorter cyclic compound that acts on several melanocortin receptor subtypes and has no approved product. Data for one cannot be applied to the other.\u003c\/span\u003e\u003c\/p\u003e\n\u003ch2 dir=\"ltr\"\u003e\u003cstrong\u003eDocumentation\u003c\/strong\u003e\u003c\/h2\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eEach PEPTYVA lot is traceable by its lot number. The Certificate of Analysis for your lot can be requested before or after purchase; see Quality \u0026amp; Documentation for what a COA typically lists.\u003c\/span\u003e\u003c\/p\u003e\n\u003ch2 dir=\"ltr\"\u003e\u003cstrong\u003eStorage and handling\u003c\/strong\u003e\u003c\/h2\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eKeep the unopened vial in its original packaging, protected from light and heat, at the temperature printed on the PEPTYVA label. Check the label and lot documentation for the storage conditions and expiry date of your lot.\u003c\/span\u003e\u003c\/p\u003e","brand":"Peptides Vallarta","offers":[{"title":"10 mg \/ A","offer_id":47106182742212,"sku":"PV-MT1-10MG","price":1760.0,"currency_code":"MXN","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0751\/8424\/2884\/files\/product1.jpg?v=1786743234"},{"product_id":"pt-141","title":"PT-141","description":"\u003ch1 dir=\"ltr\"\u003e\u003cspan\u003ePT-141 (Bremelanotide) 10 mg Research Vial\u003c\/span\u003e\u003c\/h1\u003e\n\u003cdiv dir=\"ltr\" align=\"left\"\u003e\n\u003ctable\u003e\n\u003ccolgroup\u003e \u003ccol width=\"180\"\u003e \u003ccol width=\"444\"\u003e \u003c\/colgroup\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eAlternate name\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/td\u003e\n\u003ctd\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eBremelanotide; PT-141\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eCompound class\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/td\u003e\n\u003ctd\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eSynthetic cyclic heptapeptide; melanocortin receptor agonist\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eFormat\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/td\u003e\n\u003ctd\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eVial\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eStrength(s)\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/td\u003e\n\u003ctd\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003e10 mg per vial\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eSequence\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/td\u003e\n\u003ctd\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eAc-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eMolecular formula\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/td\u003e\n\u003ctd\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eC50H68N14O10\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eMolecular weight\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/td\u003e\n\u003ctd\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003e1025.2 g\/mol\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eCAS number\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/td\u003e\n\u003ctd\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003e189691-06-3\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003ePurity\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/td\u003e\n\u003ctd\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eStated per lot on the Certificate of Analysis\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eManufacturer\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/td\u003e\n\u003ctd\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003ePEPTYVA, Mexico\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003c\/div\u003e\n\u003ch2 dir=\"ltr\"\u003e\u003cstrong\u003eWhat is PT-141?\u003c\/strong\u003e\u003c\/h2\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eThis page covers PT-141 bremelanotide in a 10 mg research vial. PT-141 was the investigational code for bremelanotide, a synthetic cyclic heptapeptide. FDA labeling describes it as having an acetylated amino terminus and a free acid at the carboxyl terminus. The vial comes from PEPTYVA in Mexico, and Peptides Vallarta offers it for laboratory research use only. It is not Vyleesi and it is not a medicine.\u003c\/span\u003e\u003c\/p\u003e\n\u003ch2 dir=\"ltr\"\u003e\u003cstrong\u003eHow does bremelanotide act at melanocortin receptors?\u003c\/strong\u003e\u003c\/h2\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eMelanocortin receptors form a family of five subtypes, MC1R to MC5R. According to the Vyleesi label, bremelanotide is an agonist that activates several of them non-selectively, in this order of potency: MC1R, MC4R, MC3R, MC5R and MC2R. At the levels reached with the approved product, binding to MC1R and MC4R is the most relevant.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eMC4R-expressing neurons are present in many areas of the central nervous system, and MC1R is expressed on melanocytes. The label states that the mechanism behind the approved indication is unknown.\u003c\/span\u003e\u003c\/p\u003e\n\u003ch2 dir=\"ltr\"\u003e\u003cstrong\u003eWhat is the approved bremelanotide product?\u003c\/strong\u003e\u003c\/h2\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eFDA approved Vyleesi (bremelanotide) on 21 June 2019. Its labeled indication is \"the treatment of premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD)\", as characterized by low sexual desire that causes marked distress or interpersonal difficulty and is not due to a co-existing medical or psychiatric condition, problems with the relationship, or the effects of a medication or drug substance.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eThe label, last revised in October 2026, states that Vyleesi is not indicated for HSDD in postmenopausal women or in men, and is not indicated to enhance sexual performance.\u003c\/span\u003e\u003c\/p\u003e\n\u003ch2 dir=\"ltr\"\u003e\u003cstrong\u003eWhat did the phase 3 clinical trials study?\u003c\/strong\u003e\u003c\/h2\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eTwo identical phase 3, randomized, double-blind, placebo-controlled clinical trials (RECONNECT, studies 301 and 302) randomized 1,267 premenopausal women with HSDD for 24 weeks. Both trials ran between January 2015 and August 2016; most participants were enrolled at US sites (96.6%), and their mean age was 39 years. The co-primary end points were changes in a desire score and in a distress score.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eNausea, flushing and headache were reported more often with bremelanotide than with placebo. The Vyleesi label lists warnings for a transient increase in blood pressure with a reduction in heart rate, focal hyperpigmentation, and nausea.\u003c\/span\u003e\u003c\/p\u003e\n\u003ch2 dir=\"ltr\"\u003e\u003cstrong\u003eWhy does the Vyleesi approval not cover this vial?\u003c\/strong\u003e\u003c\/h2\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eFDA approved a finished medicine: Vyleesi, with its own formulation, strength, container, labeling and approved population. This PEPTYVA 10 mg vial is a different product, sold as research material only.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eThe approval belongs to Vyleesi and does not extend to this research material. Grade A reflects the approval of bremelanotide inside Vyleesi; it says nothing about this vial.\u003c\/span\u003e\u003c\/p\u003e\n\u003ch2 dir=\"ltr\"\u003e\u003cstrong\u003eHow does PT-141 relate to MT-2?\u003c\/strong\u003e\u003c\/h2\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eBremelanotide was developed as an analog of melanotan II (MT-2), and the two share the same cyclic seven-residue sequence. Bremelanotide ends in a free acid while melanotan II ends in an amide, giving the formulas C50H68N14O10 and C50H69N15O9. Melanotan II has no approved product, so its data and regulatory warnings should be read separately. See the MT-2 (melanotan II) 10 mg research peptide page.\u003c\/span\u003e\u003c\/p\u003e\n\u003ch2 dir=\"ltr\"\u003e\u003cstrong\u003eDocumentation\u003c\/strong\u003e\u003c\/h2\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eYour vial's PEPTYVA lot number identifies its batch. The Certificate of Analysis for that lot is available on request, before or after purchase; the Quality \u0026amp; Documentation page describes what a COA typically lists.\u003c\/span\u003e\u003c\/p\u003e\n\u003ch2 dir=\"ltr\"\u003e\u003cstrong\u003eStorage and handling\u003c\/strong\u003e\u003c\/h2\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eStore the unopened vial sealed in its outer box, away from light and heat, at the temperature shown on the PEPTYVA label. The label and lot documentation give the storage conditions and expiry date for your lot.\u003c\/span\u003e\u003c\/p\u003e","brand":"Peptides Vallarta","offers":[{"title":"10 mg \/ A","offer_id":47106182774980,"sku":"PV-PT141-10MG","price":1860.0,"currency_code":"MXN","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0751\/8424\/2884\/files\/PT-14110mg.jpg?v=1792958350"},{"product_id":"mt-2","title":"MT-2","description":"\u003ch1\u003e\n\u003cmeta charset=\"utf-8\"\u003e \u003cstrong\u003eMT-2 (Melanotan II) 10 mg Research Peptide\u003c\/strong\u003e\n\u003c\/h1\u003e\n\u003cdiv dir=\"ltr\" align=\"left\"\u003e\n\u003ctable\u003e\n\u003ccolgroup\u003e \u003ccol width=\"180\"\u003e \u003ccol width=\"444\"\u003e \u003c\/colgroup\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eAlternate name\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/td\u003e\n\u003ctd\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eMelanotan II; MT-II\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eCompound class\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/td\u003e\n\u003ctd\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eSynthetic cyclic heptapeptide; alpha-MSH analog; non-selective melanocortin receptor agonist\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eFormat\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/td\u003e\n\u003ctd\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eVial\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eStrength(s)\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/td\u003e\n\u003ctd\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003e10 mg per vial\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eSequence\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/td\u003e\n\u003ctd\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eAc-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eMolecular formula\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/td\u003e\n\u003ctd\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eC50H69N15O9\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eMolecular weight\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/td\u003e\n\u003ctd\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003e1024.2 g\/mol\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eCAS number\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/td\u003e\n\u003ctd\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003e121062-08-6\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003ePurity\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/td\u003e\n\u003ctd\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eStated per lot on the Certificate of Analysis\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eManufacturer\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/td\u003e\n\u003ctd\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003ePEPTYVA, Mexico\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003c\/div\u003e\n\u003ch2 dir=\"ltr\"\u003e\u003cstrong\u003eWhat is MT-2?\u003c\/strong\u003e\u003c\/h2\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eMT-2 melanotan II is supplied here in a 10 mg research peptide vial. Melanotan II is a synthetic cyclic heptapeptide based on the alpha-MSH(4-10) region, with a lactam bridge between aspartic acid and lysine that closes the ring. The vial is made by PEPTYVA in Mexico and sold by Peptides Vallarta for laboratory research use only. It is not a medicine and has no approved use in people.\u003c\/span\u003e\u003c\/p\u003e\n\u003ch2 dir=\"ltr\"\u003e\u003cstrong\u003eHow does MT-2 act at melanocortin receptors?\u003c\/strong\u003e\u003c\/h2\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eMelanotan II is a potent but non-selective melanocortin receptor agonist. A 2010 pharmacology study described it as superpotent but nonselective and tested it, with 31 modified derivatives, for binding and activation at melanocortin receptor subtypes 1, 3, 4 and 5.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eThese receptors sit in different tissues. MC1R is expressed on melanocytes, while MC4R is found on neurons in many areas of the central nervous system. A non-selective agonist therefore acts on several pathways at once, and researchers have used MT-2 as a starting point when designing more selective analogs.\u003c\/span\u003e\u003c\/p\u003e\n\u003ch2 dir=\"ltr\"\u003e\u003cstrong\u003eWhat human evidence exists for MT-2?\u003c\/strong\u003e\u003c\/h2\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eHuman evidence is limited to small, early studies. A 1996 single-blind, placebo-controlled pilot phase I clinical trial enrolled three male volunteers. It measured skin pigmentation by reflectance and recorded adverse events, including nausea at most levels tested and somnolence and fatigue in one participant at the highest level.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eA study of three people cannot establish safety or efficacy. No later program led to an approved melanotan II product, and Drugs@FDA lists none.\u003c\/span\u003e\u003c\/p\u003e\n\u003ch2 dir=\"ltr\"\u003e\u003cstrong\u003eWhat have regulators said about melanotan products?\u003c\/strong\u003e\u003c\/h2\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eRegulators have warned about melanotan products sold outside approved channels. FDA lists Melanotan II on its page of bulk drug substances that may present significant safety risks, in the group whose compounding nominations were withdrawn. FDA notes a possible immunogenicity risk and states that published case reports discuss serious adverse events, including melanoma.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eAustralia's Therapeutic Goods Administration stated in 2017 that melanotan products are not included on the Australian Register of Therapeutic Goods, have not been assessed as safe and effective, are not approved for sale in Australia, and may cause serious side effects.\u003c\/span\u003e\u003c\/p\u003e\n\u003ch2 dir=\"ltr\"\u003e\u003cstrong\u003eWhy is MT-2 graded C?\u003c\/strong\u003e\u003c\/h2\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eMT-2 is graded C because its human evidence is limited to small, early studies. The pilot phase I data come from three volunteers, and later reports include published case reports of serious adverse events in people using unlicensed products, as FDA notes. No melanotan II product is approved by FDA or included on Australia's register, and efficacy for any use is not established.\u003c\/span\u003e\u003c\/p\u003e\n\u003ch2 dir=\"ltr\"\u003e\u003cstrong\u003eHow does MT-2 relate to MT-1 and PT-141?\u003c\/strong\u003e\u003c\/h2\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eMT-1 (afamelanotide) is a linear 13-residue peptide that binds mainly MC1R and is approved as a branded implant for one rare condition. MT-2 is shorter, cyclic and non-selective, and has no approved product.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003ePT-141 (bremelanotide) shares MT-2's cyclic seven-residue sequence. PubChem lists it with a free acid at the C-terminus where MT-2 carries an amide, which changes the formula to C50H68N14O10. Even small structural differences like this mean that data and approvals for one compound do not apply to the others. Compare the PT-141 (bremelanotide) 10 mg research vial page for that compound's regulatory history.\u003c\/span\u003e\u003c\/p\u003e\n\u003ch2 dir=\"ltr\"\u003e\u003cstrong\u003eDocumentation\u003c\/strong\u003e\u003c\/h2\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eThe PEPTYVA lot number on the label links your vial to its batch records. Ask us for the lot's Certificate of Analysis at any time; the Quality \u0026amp; Documentation page explains what a COA typically shows.\u003c\/span\u003e\u003c\/p\u003e\n\u003ch2 dir=\"ltr\"\u003e\u003cstrong\u003eStorage and handling\u003c\/strong\u003e\u003c\/h2\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eStore the unopened vial sealed in its original box, out of light and away from heat, at the temperature given on the PEPTYVA label. Confirm storage conditions and the expiry date on the label and lot documentation.\u003c\/span\u003e\u003c\/p\u003e","brand":"Peptides Vallarta","offers":[{"title":"10 mg \/ C","offer_id":47106182807748,"sku":"PV-MT2-10MG","price":1760.0,"currency_code":"MXN","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0751\/8424\/2884\/files\/MT-210mg.jpg?v=1792958585"}],"url":"https:\/\/peptidesvallarta.com\/es\/collections\/melanocortins-sexual-health.oembed","provider":"Peptides Vallarta","version":"1.0","type":"link"}